E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Attention Deficit Hyperactivity Disorder (ADHD) |
Aandachtstekortstoornis met Hyperactiviteit (ADHD) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this trial is to study the effects of mindfulness training combined with Mindful Parenting training versus methylphenidate in children and youngsters with ADHD on outcome measures of attention, hyperactivity and impulsivity. |
Het primaire doel van deze studie is om de effecten van mindfulness training gecombineerd met Mindful Parenting training versus methylfenidaat te onderzoeken in kinderen en jongeren met ADHD op uitkomstmaten van aandacht, hyperactiviteit en impulsiviteit. |
|
E.2.2 | Secondary objectives of the trial |
A seondary aim of this study is to evaluate the cost-effectiveness of mindfulness training + Mindful Parenting training as compared to methylphenidate in this group of children. |
Een tweede doel van deze studie is om de kosteneffectiviteit te evalueren van mindfulness training + Mindful Parenting training vergeleken met methylfenidaat bij deze groep kinderen. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- The child is between 9 and 18 years of age
- The child has a DSM classification of ADHD
- ADIS-C is administered
- (Estimated) IQ > 80
- At least one parent is willing to participate in the Mindful Parenting training |
- Het kind is tussen de 9 en 19 jaar oud
- Het kind heeft een DSM classificatie ADHD
- ADIS-C wordt afgenomen
- (Geschat) IQ > 80
- Tenminste een ouder is bereid deel te nemen aan de Mindful Parenting training |
|
E.4 | Principal exclusion criteria |
- (Estimated) IQ < 80
- Suicidal ideation
- Suffering from psychosis or schizophrenia
- Co-morbid autism or Conduct Disorder
- Current or previous use of methylphenidate
- Participation in a currently active other psychological intervention |
- (Geschat) IQ < 80
- Suicidale ideaties
- Lijden aan psychose of schizofrenie
- Co-morbide autisme of Conduct Disorder
- Huidig of eerder gebruik van methylfenidaat
- Deelname aan huidig lopende actieve andere psychologische interventie |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Our primary outcome measure is attention, hyperactivity and impulsivity in the child. |
Onze primaire uitkomstmaat is aandacht, hyperactiviteit en impulsiviteit bij het kind. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Directly after the last participant finished his/her treatment |
Direct na het einde van de laatste behandeling van de laatste patient |
|
E.5.2 | Secondary end point(s) |
Secondary outcome measures are symptoms of anxiety and depression, sleep, parents own symptomatology, parental stress and mindfulness. |
Secundaire uitkomstmaten zijn symptomen van angst en depressie, slaap, ouders' eigen symptomatologie, ouderlijke stress en mindfulness. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Directly after the last participant finished his/her treatment |
Direct na het einde van de laatste behandeling van de laatste patient |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Mindfulness Training |
Mindfulness Training |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |